Skip to content

The Prospective Intervention for Chronic Obstructive Pulmonary Disease Patients Under Severe Air Pollution (PICAP) in Beijing: protocol of a multi-center randomized controlled trial

The Prospective Intervention for Chronic Obstructive Pulmonary Disease Patients Under Severe Air Pollution (PICAP) in Beijing: protocol of a multi-center randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17010759
Enrollment
Unknown
Registered
2017-03-02
Start date
2017-02-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Intervention:sdg
Control:Maintain the original medication

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) aged at 40–80 years old; 2) spirometry confirmed diagnose of COPD with at least one exacerbation before, and stable for at least three months; 3) quit smoking for more than six months; 4) be able to engage in daily activities; 5) have willing to participate in this study, follow the research program and have the ability to sign the informed consent; 6) Beijing residents; 7) can be contacted;

Exclusion criteria

Exclusion criteria: 1) history of asthma, lung cancer, active pulmonary tuberculosis, bronchiectasis, diffuse lung disease (interstitial pneumonia, pulmonary sarcoidosis, occupational lung disease, sarcoidosis et al) and pleural disease; 2) history of lobectomy and / or lung transplantation; 3) predicted life expectancy less than 3 years; 4) history of severe psychiatric illnesses, mental disorders, neurological disorders, malignant tumors, chronic liver disease, heart failure, autoimmune diseases, chronic kidney disease; 5) Never engage in outdoor activities; 6)?? 7) expected to move out of the city in 3 years; 8) Plan to carry out an indoor redecoration during the study; 9) Alcoholism, drug abuse or abuse of toxic solvents; 10) Allergic to the study drug or its ingredients, or have a clear contraindication of it; 11) Participation in another clinical trial; 12) Cannot finish long term follow-up or poor compliance; 13) Do not provide consent.

Design outcomes

Primary

MeasureTime frame
frequency of exacerbation per year;

Secondary

MeasureTime frame
number of unplanned outpatient visits due to exacerbation per year;number of emergency visits due to exacerbation per year;number of hospitalization due to exacerbation per year;cost due to exacerbation per year;Mortality rate associated with COPD exacerbation;

Countries

China

Contacts

Public ContactGuangfa Wang

Peking University First Hospital

wangguangfa@hotmail.com+86 13810644029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026